Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company is headquartered in Kennesaw, Georgia and currently employs 1,800 full-time employees. The firm is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.
How did AORT's recent EPS compare to expectations?
The most recent EPS for Artivion Inc is $0.08, beating expectations of $0.05.
How did Artivion Inc AORT's revenue perform in the last quarter?
Artivion Inc revenue for the last quarter is $0.08
What is the revenue estimate for Artivion Inc?
According to 10 of Wall street analyst, the revenue estimate of Artivion Inc range from $134.4M to $119.27M
What's the earning quality score for Artivion Inc?
Artivion Inc has a earning quality score of B+/57.86774. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Artivion Inc report earnings?
Artivion Inc next earnings report is expected in 2026-08-05
What are Artivion Inc's expected earnings?
Artivion Inc expected earnings is $118.11M, according to wall-street analysts.
Did Artivion Inc beat earnings expectations?
Artivion Inc recent earnings of $116.34M does not beat expectations.